Novo Nordisk: licensing agreement with Heartseed

(CercleFinance.com) - Novo Nordisk and Japanese biotech company Heartseed announced Friday that the first patient has received their experimental gene therapy aimed at restoring heart function in individuals with heart failure.


Heartseed has enrolled the first patient in this Phase 1/2 study, which will evaluate the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease in 10 patients.

Four weeks after dosing, an independent review committee reviewed the initial data collected and gave the green light for the trial to continue.

HS-001 consists of allogeneic ventricular cardiomyocyte spheroids that electrically couple with the patient's myocardium to improve cardiac output through remuscularization and to form new blood vessels (neovascularization).


Copyright (c) 2023 CercleFinance.com. All rights reserved.